Role of ischemia-modified albumin in estimating the extent and scope of cardiac ischemia in patients with ST elevation myocardial infarction
Language English Country Japan Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Analysis of Variance MeSH
- Angioplasty, Balloon, Coronary MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Myocardial Infarction blood diagnosis etiology pathology therapy MeSH
- Myocardial Ischemia blood complications diagnosis pathology therapy MeSH
- Creatine Kinase, MB Form blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Serum Albumin, Human MeSH
- Linear Models MeSH
- Myocardium pathology MeSH
- Necrosis MeSH
- Predictive Value of Tests MeSH
- Prognosis MeSH
- Aged MeSH
- Serum Albumin MeSH
- Severity of Illness Index MeSH
- Troponin T blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Biomarkers MeSH
- ischemia-modified albumin MeSH Browser
- Creatine Kinase, MB Form MeSH
- Serum Albumin, Human MeSH
- Serum Albumin MeSH
- Troponin T MeSH
Ischemia-modified albumin (IMA) is a laboratory biomarker of cardiac ischemia. Our study aims to determine whether IMA can estimate or represent to any degree the extent of myocardial ischemia. We expect that the higher the marker of cardiac necrosis (maximum value after serial measurements) the greater the preceding cardiac ischemia, indicated by IMA in patients diagnosed with STEMI prior to direct percutaneous coronary intervention (PCI). We studied 216 patients indicated for direct PCI with a diagnosis of ST elevation myocardial infarction. Biochemical analysis of IMA was carried out using the albumin cobalt binding (ACB®) test. We also obtained relevant values for markers of myocardial necrosis (CK, CK-MB, cTnT). In all patients, there was an increased level of IMA prior to the procedure (116 ± 16.9 kU/l); also raised were levels of CK (17.32 μkat/l), CK-MB (4.85 μkat/l) and cTnT (2.97 μg/l) taken as the maximum values obtained after serial measurements at 12, 18, and 24 h after the procedure. We observed that there was no significant association between increase in IMA and cTnT (R2 = 0.0068, p = 0.483). This was also the case for CK-MB (R2 = 0.0011, p = 0.637). IMA does not estimate the extent of ischemia in patients with ST elevation myocardial infarction. However, its absence can be used qualitatively to rule out cardiac ischemia.
See more in PubMed
Heart. 2006 Jan;92(1):113-4 PubMed
Clin Chem Lab Med. 2007;45(2):261-2 PubMed
J Am Coll Cardiol. 2007 Jun 19;49(24):2375-6; author reply 2376-7 PubMed
Heart Vessels. 2010 Mar;25(2):87-91 PubMed
Scand J Clin Lab Invest. 2010 Jul;70(4):244-51 PubMed
J Clin Lab Anal. 2010;24(4):273-7 PubMed
Clin Chim Acta. 2009 May;403(1-2):114-20 PubMed
Clin Chim Acta. 2008 Jan;387(1-2):120-7 PubMed
Am J Cardiol. 2003 Aug 1;92(3):322-4 PubMed
Eur Heart J. 2007 Feb;28(3):278-91 PubMed
Clin Chim Acta. 1983 Mar 14;128(2-3):329-35 PubMed
Clin Chim Acta. 2006 May;367(1-2):77-80 PubMed
Clin Chem. 2004 Sep;50(9):1656-60 PubMed
Clin Chem. 2004 Jun;50(6):1063-5 PubMed
Circulation. 1982 Apr;65(4):756-64 PubMed
Clin Chem. 2002 Sep;48(9):1432-6 PubMed
Clin Chem Lab Med. 2004 Apr;42(4):455-61 PubMed
Ann Clin Biochem. 2006 Nov;43(Pt 6):500-2 PubMed
Heart Vessels. 2010 Sep;25(5):374-8 PubMed
Int J Cardiol. 2005 Mar 10;99(1):77-81 PubMed
Am J Cardiol. 2004 Jan 1;93(1):88-90 PubMed
Clin Chem. 2001 Mar;47(3):464-70 PubMed
Heart Vessels. 2008 May;23(3):174-80 PubMed
Clin Chim Acta. 2008 Feb;388(1-2):196-9 PubMed
